Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

IN.PACT™ AV Access Post-Approval Study (PAS002)

NCT04543539 · View on ClinicalTrials.gov ↗

Study Summary

Long-term safety will be summarized

Interventions

  • COMBINATION_PRODUCT IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort
  • COMBINATION_PRODUCT IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort

Study Locations (20)

New York

  • Albany Medical College — Albany
  • The Mount Sinai Hospital — New York
  • Staten Island University Hospital — Staten Island

California

  • Cedars-Sinai Heart Institute — Los Angeles
  • Stanford University Medical Center — Stanford

Florida

  • NCH Healthcare System — Naples
  • Coastal Vascular and Interventional — Pensacola

South Carolina

  • MUSC Health Dialysis Access Institute — Orangeburg
  • Spartanburg Regional Medical Center — Spartanburg

Connecticut

  • Yale New Haven Hospital — New Haven

District of Columbia

  • Medstar Washington Hospital — Washington D.C.

Iowa

  • University of Iowa — Iowa City

Michigan

  • University of Michigan Health System - University Hospital — Ann Arbor

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2020-11-13
Est. Completion 2029-02

Sponsor

Medtronic

14 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04543539

The ClinicalTrials.gov registry entry for NCT04543539 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic, which has 14 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Arteriovenous Fistula appearing as the primary indexed condition, and to 2 interventions — of which IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04543539 reports 20 study locations spanning 15 distinct geographic areas — top geographies include New York, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04543539 about?

NCT04543539 is a clinical study titled "IN.PACT™ AV Access Post-Approval Study (PAS002)". Long-term safety will be summarized

What is the current status of trial NCT04543539?

This trial is currently active not recruiting. The enrollment target is 240 participants. The study started on 2020-11-13. Estimated completion is 2029-02.

What conditions does trial NCT04543539 study?

This clinical trial studies the following conditions: Arteriovenous Fistula, Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04543539?

The interventions under investigation include: IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort (COMBINATION_PRODUCT), IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04543539?

This trial is sponsored by Medtronic, which has 14 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04543539 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial